Omalizumab is not just an anti-immunoglobulin E.

IF 2.9 4区医学 Q2 DERMATOLOGY

Journal of Dermatological Treatment Pub Date : 2022-09-01 Epub Date: 2022-06-20 DOI:10.1080/09546634.2022.2089326

Goknur Ozaydin-Yavuz, Ibrahim Halil Yavuz, Hüseyin Serhat İnalöz, Cagdas Boyvadoglu

{"title":"Omalizumab is not just an anti-immunoglobulin E.","authors":"Goknur Ozaydin-Yavuz, Ibrahim Halil Yavuz, Hüseyin Serhat İnalöz, Cagdas Boyvadoglu","doi":"10.1080/09546634.2022.2089326","DOIUrl":null,"url":null,"abstract":"Introduction and purpose: The mechanism of omalizumab in urticaria is not literally known. Omalizumab may affect receptors on the mast cell surface in other ways, especially other than Fc epsilon RI.Materials and methods: Thirty patients who were treated with omalizumab with the diagnosis of chronic urticaria were included in the study. For serum vasoactive intestinal peptide (VIP), kallikrein (KAL), and substance p (SP) values, 5 mL of blood was taken from the patients. These bloods were centrifuged for 5 min and stored at -80° until the levels were measured. The changes in values measured at baseline, third month, and sixth month were analyzed by Friedman test. A value of p < 0.05 was considered statistically significant results.Results: While SP, KAL, and VIP values increased continuously, it was observed that the D-dimer value decreased.Conclusion: This study shows that omalizumab can affect mast cells other than IgE. To the best of our knowledge, this is the first study to show the relationship between omalizumab and VIP.","PeriodicalId":15639,"journal":{"name":"Journal of Dermatological Treatment","volume":" ","pages":"2858-2861"},"PeriodicalIF":2.9000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dermatological Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09546634.2022.2089326","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Introduction and purpose: The mechanism of omalizumab in urticaria is not literally known. Omalizumab may affect receptors on the mast cell surface in other ways, especially other than Fc epsilon RI.

Materials and methods: Thirty patients who were treated with omalizumab with the diagnosis of chronic urticaria were included in the study. For serum vasoactive intestinal peptide (VIP), kallikrein (KAL), and substance p (SP) values, 5 mL of blood was taken from the patients. These bloods were centrifuged for 5 min and stored at -80° until the levels were measured. The changes in values measured at baseline, third month, and sixth month were analyzed by Friedman test. A value of p < 0.05 was considered statistically significant results.

Results: While SP, KAL, and VIP values increased continuously, it was observed that the D-dimer value decreased.

Conclusion: This study shows that omalizumab can affect mast cells other than IgE. To the best of our knowledge, this is the first study to show the relationship between omalizumab and VIP.

查看原文本刊更多论文

Omalizumab不仅仅是一种抗免疫球蛋白E。

简介和目的:omalizumab治疗荨麻疹的机制尚不清楚。Omalizumab可能以其他方式影响肥大细胞表面的受体，特别是Fc epsilon RI以外的受体。材料和方法:本研究纳入30例诊断为慢性荨麻疹且接受奥玛珠单抗治疗的患者。取患者血清血管活性肠肽(VIP)、激肽素(KAL)、p物质(SP)测定5 mL。这些血液离心5分钟，并在-80°保存，直到测量水平。采用Friedman检验分析基线、第3个月、第6个月测量值的变化。结果:在SP、KAL、VIP值不断升高的同时，观察到d -二聚体值下降。结论:本研究表明omalizumab可影响IgE以外的肥大细胞。据我们所知，这是第一个显示omalizumab和VIP之间关系的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Dermatological Treatment 医学-皮肤病学

CiteScore

6.50

自引率

0.00%

发文量

145

审稿时长

6-12 weeks

期刊介绍： The Journal of Dermatological Treatment covers all aspects of the treatment of skin disease, including the use of topical and systematically administered drugs and other forms of therapy. The Journal of Dermatological Treatment is positioned to give dermatologists cutting edge information on new treatments in all areas of dermatology. It also publishes valuable clinical reviews and theoretical papers on dermatological treatments.